(MASS) 908 Devices - Ratings and Ratios
Portable,Mass,Spec,Analyzers Security,Detection,Labs Breath,Diagnostic,Devices
MASS EPS (Earnings per Share)
MASS Revenue
Description: MASS 908 Devices
908 Devices Inc. (NASDAQ:MASS) is a commercial-stage technology company that specializes in providing innovative mass spectrometry devices for various industries, including life sciences research, bioprocessing, and pharmaceuticals. The companys product portfolio includes handheld and desktop devices, such as MX908, Rebel, and Maverick, which offer real-time analysis and monitoring capabilities.
To evaluate the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of revenue. Given the companys negative P/E ratio and RoE of -12.60, it is likely that 908 Devices is still in a growth phase, investing heavily in research and development, sales, and marketing. The companys market capitalization of $253.54M USD suggests a moderate level of investor confidence.
From a technical analysis perspective, the stocks price is currently at $6.94, slightly below its 20-day simple moving average (SMA) of $6.96. The 50-day SMA is at $6.16, and the 200-day SMA is at $3.90, indicating a longer-term uptrend. The average true range (ATR) is $0.40, representing a 5.69% daily price volatility. This information can be used to inform trading decisions and risk management strategies.
To further analyze 908 Devices prospects, we can examine the companys competitive landscape, market trends, and product pipeline. The life sciences and bioprocessing industries are rapidly evolving, with a growing demand for innovative analytical technologies. 908 Devices products, such as the MX908 and Rebel, are well-positioned to capitalize on this trend. By monitoring the companys progress in terms of revenue growth, product development, and market adoption, investors can make more informed decisions about their investment in MASS.
MASS Stock Overview
| Market Cap in USD | 222m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2020-12-18 |
MASS Stock Ratings
| Growth Rating | -14.6% |
| Fundamental | 19.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 50.5% |
| Analyst Rating | 4.50 of 5 |
MASS Dividends
Currently no dividends paidMASS Growth Ratios
| Growth Correlation 3m | -74.9% |
| Growth Correlation 12m | 77.3% |
| Growth Correlation 5y | -92.8% |
| CAGR 5y | -26.28% |
| CAGR/Max DD 3y | -0.29 |
| CAGR/Mean DD 3y | -0.42 |
| Sharpe Ratio 12m | -0.29 |
| Alpha | 0.34 |
| Beta | 0.468 |
| Volatility | 83.17% |
| Current Volume | 619.6k |
| Average Volume 20d | 276k |
| Stop Loss | 6.1 (-6.6%) |
| Signal | 1.74 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-18.4m TTM) > 0 and > 6% of Revenue (6% = 3.62m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA -3.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 195.6% (prev 168.4%; Δ 27.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -28.7m <= Net Income -18.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (35.9m) change vs 12m ago 5.33% (target <= -2.0% for YES) |
| Gross Margin 48.59% (prev 49.65%; Δ -1.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.17% (prev 25.24%; Δ 4.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -6.98
| (A) 0.62 = (Total Current Assets 147.9m - Total Current Liabilities 29.7m) / Total Assets 191.7m |
| (B) -1.11 = Retained Earnings (Balance) -212.5m / Total Assets 191.7m |
| warn (B) unusual magnitude: -1.11 — check mapping/units |
| (C) -0.33 = EBIT TTM -65.8m / Avg Total Assets 200.2m |
| (D) -4.95 = Book Value of Equity -212.5m / Total Liabilities 42.9m |
| Total Rating: -6.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.01
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -26.30% = -5.0 |
| 3. FCF Margin -51.07% = -7.50 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda -0.22 = -2.50 |
| 6. ROIC - WACC (= -54.80)% = -12.50 |
| 7. RoE -13.32% = -2.22 |
| 8. Rev. Trend 24.80% = 1.86 |
| 9. EPS Trend -22.57% = -1.13 |
What is the price of MASS shares?
Over the past week, the price has changed by +14.56%, over one month by +4.15%, over three months by -11.16% and over the past year by +78.42%.
Is 908 Devices a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MASS is around 5.55 USD . This means that MASS is currently overvalued and has a potential downside of -15.01%.
Is MASS a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MASS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 53.1% |
| Analysts Target Price | 10 | 53.1% |
| ValueRay Target Price | 6.1 | -6.3% |
Last update: 2025-09-18 04:37
MASS Fundamental Data Overview
CCE Cash And Equivalents = 118.6m USD (Cash And Short Term Investments, last quarter)
P/S = 3.3906
P/B = 1.4937
Beta = 0.368
Revenue TTM = 60.4m USD
EBIT TTM = -65.8m USD
EBITDA TTM = -60.7m USD
Long Term Debt = 13.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 433.0k USD (from shortTermDebt, last quarter)
Debt = 13.6m USD (Calculated: Short Term 433.0k + Long Term 13.2m)
Net Debt = -57.3m USD (from netDebt column, last quarter)
Enterprise Value = 117.3m USD (222.3m + Debt 13.6m - CCE 118.6m)
Interest Coverage Ratio = unknown (Ebit TTM -65.8m / Interest Expense TTM 0.0)
FCF Yield = -26.30% (FCF TTM -30.8m / Enterprise Value 117.3m)
FCF Margin = -51.07% (FCF TTM -30.8m / Revenue TTM 60.4m)
Net Margin = -30.53% (Net Income TTM -18.4m / Revenue TTM 60.4m)
Gross Margin = 48.59% ((Revenue TTM 60.4m - Cost of Revenue TTM 31.1m) / Revenue TTM)
Tobins Q-Ratio = -0.55 (set to none) (Enterprise Value 117.3m / Book Value Of Equity -212.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 13.6m)
Taxrate = 21.0% (US default)
NOPAT = -65.8m (EBIT -65.8m, no tax applied on loss)
Current Ratio = 4.98 (Total Current Assets 147.9m / Total Current Liabilities 29.7m)
Debt / Equity = 0.09 (Debt 13.6m / last Quarter total Stockholder Equity 148.8m)
Debt / EBITDA = -0.22 (Net Debt -57.3m / EBITDA -60.7m)
Debt / FCF = -0.44 (Debt 13.6m / FCF TTM -30.8m)
Total Stockholder Equity = 138.5m (last 4 quarters mean)
RoA = -9.62% (Net Income -18.4m, Total Assets 191.7m )
RoE = -13.32% (Net Income TTM -18.4m / Total Stockholder Equity 138.5m)
RoCE = -43.38% (Ebit -65.8m / (Equity 138.5m + L.T.Debt 13.2m))
RoIC = -47.51% (NOPAT -65.8m / Invested Capital 138.5m)
WACC = 7.29% (E(222.3m)/V(235.9m) * Re(7.74%)) + (D(13.6m)/V(235.9m) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 99.24 | Cagr: 1.16%
Discount Rate = 7.74% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -30.8m)
EPS Correlation: -22.57 | EPS CAGR: -10.01% | SUE: -0.88 | # QB: 0
Revenue Correlation: 24.80 | Revenue CAGR: -6.75% | SUE: 0.92 | # QB: 1
Additional Sources for MASS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle